KalVista (KALV) announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, has granted Pendopharm, a division of Pharmascience, the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat in Canada. Sebetralstat is an investigational, oral on-demand treatment for hereditary angioedema. Financial terms of the agreement are not being disclosed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- Optimistic Buy Rating for KalVista Pharmaceuticals Amidst Positive FDA Interactions and Imminent Decision on Sebetralstat
- Stifel calls report of Makary pushing for KalVista CRL ‘highly surprising’
- KalVista selloff on Endpoints report unwarranted, says JonesResearch
- FDA Commissioner pushed to reject KalVista drug, Endpoints News says
- KalVista volatile after Endpoints report on FDA Commissioner objection